Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

20P - Exploring the impact of neoadjuvant therapy on suicide risk among breast cancer patients: A comprehensive retrospective study and mendelian randomization analysis

Date

07 Dec 2024

Session

Poster Display session

Presenters

Yushuai Yu

Citation

Annals of Oncology (2024) 35 (suppl_4): S1405-S1414. 10.1016/annonc/annonc1683

Authors

Y. Yu

Author affiliations

  • Department Of Breast Surgery, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, 350001 - Fuzhou/CN

Resources

This content is available to ESMO members and event participants.

Abstract 20P

Background

Suicide among breast cancer (BC) patients is a significant concern. Previous research indicates increased psychological distress in these patients, but the effect of treatment types like neoadjuvant therapy on suicide risk is underexplored.

Methods

Utilizing data from the SEER 17 registries, this retrospective study included 435,070 female BC patients diagnosed between 2000 and 2010. Standardized Mortality Ratio (SMR) was calculated to compare observed suicide rates in our cohort to expected rates based on general population data. Suicide risks were analyzed using Poisson regression, and Mendelian randomization (MR) analysis was employed to examine the genetic correlations between BC and suicide.

Results

Peak suicide occurrences were noted at approximately 50.44 months post-diagnosis, with those receiving neoadjuvant therapy showing earlier suicide times at 45.13 months. SMR for patients aged 18-44 was lower in the neoadjuvant group [1.05 (95% CI: 0.45-2.06) compared to the adjuvant group [1.43 (95% CI: 1.00-1.98)]. Triple-negative BC patients undergoing adjuvant therapy exhibited the highest SMR [3.63 (95% CI: 1.33-7.90)]. Socioeconomic factors, including income and race, significantly influenced suicide risks, with middle-income white patients benefiting most from neoadjuvant therapy. Conversely, higher-income patients exhibited increased suicide risks. Mendelian Randomization (MR) analysis revealed no genetic correlation between BC and suicide, suggesting that external factors predominantly influence these outcomes.

Conclusions

Neoadjuvant therapy appears to reduce the risk of suicide in certain subgroups of BC patients. Our study underscores the importance of considering socioeconomic and demographic factors when assessing mental health impacts on breast cancer patient.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.